immunology Archives -

News/ News/ R&D

AbbVie and Cugene partner to tackle autoimmune diseases

Joy Persaud AbbVie, autoimmune disease, immunology, pharma, R&D, Rinvoq 0 Comment

AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The

AbbVie and Cugene partner to tackle autoimmune diseases

https://pharmaphorum.com/news/abbvie-and-cugene-partner-to-tackle-autoimmune-diseases/

Boehringer Ingelheim, Biberach, Germany, February 2007

News/ News/ Sales and Marketing

Boehringer plans €25bn R&D spend, fuelled by Jardiance

Phil Taylor Boehringer Ingelheim, Financial, immunology, Jardiance, Oncology, R&D 0 Comment

Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over

Boehringer plans €25bn R&D spend, fuelled by Jardiance

https://pharmaphorum.com/news/boehringer-plans-e25bn-rd-spend-fuelled-by-jardiance/

News/ News/ R&D

Study uncovers new Alzheimer’s genes, links to immune disruption

Phil Taylor Alzheimer's disease, clinical trials, genetics, immunology, neurology, R&D 0 Comment

The largest-ever study of genetics in Alzheimer’s disease patients has identified 42 new genes that appear to be

Study uncovers new Alzheimer’s genes, links to immune disruption

https://pharmaphorum.com/news/study-uncovers-new-alzheimers-genes-links-to-immune-disruption/

News/ News/ R&D

Equillium triples clinical pipeline with $329m Bioniz takeover

Phil Taylor alopecia, Bioniz, coeliac disease, Equillium, graft versus host disease, immunology, lymphoma, M&A 0 Comment

Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to

Equillium triples clinical pipeline with $329m Bioniz takeover

https://pharmaphorum.com/news/equillium-triples-clinical-pipeline-with-329m-bioniz-takeover/

News/ News/ R&D

Another big AI deal as Sanofi taps Exscientia for 15 new drugs

Phil Taylor Artifical Intellgence, digital health, drug discovery, exscientia, immunology, Oncology, partnering, Sanofi 0 Comment

If the last couple of days is an indication, 2022 is already shaping up to be the year

Another big AI deal as Sanofi taps Exscientia for 15 new drugs

https://pharmaphorum.com/news/another-big-ai-deal-as-sanofi-taps-exscientia-for-15-new-drugs/

News/ News/ R&D

Dupixent scores a first in rare skin disease prurigo nodularis

Phil Taylor dermatology, Dupixent, immunology, prurigo nodularis, rare disease, Regeneron, Sanofi 0 Comment

Sanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising

Dupixent scores a first in rare skin disease prurigo nodularis

https://pharmaphorum.com/news/dupixent-scores-a-first-in-rare-skin-disease-prurigo-nodularis/

News/ News/ Sales and Marketing

FDA clears first “interchangeable” Humira biosimilar

Phil Taylor AbbVie, biosimilar, Boehringer Ingelheim, Cyltezo, Humira, immunology, regulatory approval 0 Comment

Biosimilar competition to AbbVie’s big-selling Humira drug in the US has just been ratcheted up by the FDA

FDA clears first “interchangeable” Humira biosimilar

https://pharmaphorum.com/news/fda-clears-first-interchangeable-humira-biosimilar/

News/ News/ R&D

Rome Therapeutics raises $77m for junk DNA-targeting drugs

Phil Taylor Biotech, financing, immunology, Oncology, Rome Therapeutics 0 Comment

Startup Rome Therapeutics has raised $77 million in second-round financing to help mine sequences of DNA – which

Rome Therapeutics raises $77m for junk DNA-targeting drugs

https://pharmaphorum.com/news/rome-therapeutics-raises-77m-for-junk-dna-targeting-drugs/

News/ News/ R&D

Novartis’ transplant drug hope iscalimab flunks mid-stage trial

Phil Taylor antibody, immunology, iscalimab, Novartis, R&D, transplant 0 Comment

Novartis hopes of improving on tacrolimus as the standard drug for preventing organ rejection in transplant patients have

Novartis’ transplant drug hope iscalimab flunks mid-stage trial

https://pharmaphorum.com/news/novartis-transplant-drug-hope-iscalimab-flunks-mid-stage-trial/

Trending

immunology

Login